Cipla gets 1 inspectional observation from USFDA for Maha facility

Mumbai: Pharma giant Cipla has informed through a recent BSE filing that the Company has received 1 inspectional observation in Form 483 from the United States Food and Drug Administration (USFDA) at the conclusion of the inspection at Kurkumbh manufacturing facility.

The inspection was held from 29th April, 2024 to 8th May, 2024.

"A routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at manufacturing facility of the Company located in Kurkumbh, Maharashtra, India from 29th April, 2024 to 8th May, 2024," Cipla stated.

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. 

"The Company will work closely with the USFDA and is committed to address this observation comprehensively within stipulated time," Drug major added.

Read also: Cipla Health to acquire Ivia Beaute's cosmetics, personal care distribution and marketing business for Rs 130 crore

In April, the Medical Dialogues team reported that Cipla received six inspectional observations in Form 483 from the USFDA at the conclusion of a routine current Good Manufacturing Practices (cGMP) inspection at the company's manufacturing facility located in Patalganga, Maharashtra, India.  

Read also: Cipla gets 6 USFDA observations for Maha facility

Read also: Cipla Gets CDSCO Panel Nod To import, market Human Insulin inhalation powder with inhaler